Get the Stockscreener App
10.46
3.86%
-0.42
After Hours:
10.44
-0.02
-0.19%
Emergent Biosolutions Inc stock is traded at $10.46, with a volume of 855.06K.
It is down -3.86% in the last 24 hours and up +1.85% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$10.88
Open:
$10.85
24h Volume:
855.06K
Relative Volume:
0.74
Market Cap:
$566.77M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.7087
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-5.85%
1M Performance:
+1.85%
6M Performance:
+6.09%
1Y Performance:
+570.51%
1-Day Range:
$10.36
$11.00
1-Week Range:
$10.12
$11.75
52-Week Range:
$1.47
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.46 | 566.77M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions (NYSE:EBS) Trading Down 7%Here's Why - MarketBeat
Emergent BioSolutions (NYSE:EBS) Shares Down 3.9%What's Next? - MarketBeat
Where are the Opportunities in (EBS) - Stock Traders Daily
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent BioSolutions’ CEO Sold $11 Million worth of stock before error in Baltimore went public - WBAL Radio
Emergent BioSolutions Inc. to Host Earnings Call - ACCESS Newswire
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Emergent BioSolutions Inc (EBS) Stock Price Up 3.4% on Jan 24 - GuruFocus.com
Emergent BioSolutions (NYSE:EBS) Trading 7.2% HigherTime to Buy? - MarketBeat
Emergent seeking to reverse fortunes and become a major overdose treatment player - Pharmaceutical Technology
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Emergent BioSolutions stock reaffirms buy rating on contract modification - MSN
Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Emergent BioSolutions stock reaffirms buy rating on contract modification By Investing.com - Investing.com UK
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts - Benzinga
EBS (Emergent BioSolutions) Revenue : $1,094 Mil (TTM As of Sep. 2024) - GuruFocus.com
Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News
Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
EBS (Emergent BioSolutions) Free Cash Flow : $138 Mil (TTM As of Sep. 2024) - GuruFocus.com
Emergent BioSolutions gains exclusive commercial rights to KLOXXADO - MSN
Africa CDC Launches Groundbreaking Pan-African Mpox Treatment Trial in DRC - StockTitan
Emergent BioSolutions presents at healthcare conference By Investing.com - Investing.com Australia
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference - TipRanks
Emergent BioSolutions presents at healthcare conference - Investing.com
Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock - MarketBeat
StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy - MarketBeat
Emergent secures rights to KLOXXADO nasal spray By Investing.com - Investing.com Canada
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - The Malaysian Reserve
Hikma announces exclusive commercial partnership with Emergent B - GuruFocus.com
Emergent secures rights to KLOXXADO nasal spray - Investing.com
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - The Manila Times
Emergent BioSolutions: Stock Is A Likely Winner In 2025 (NYSE:EBS) - Seeking Alpha
Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution - StockTitan
Emergent BioSolutions Expands Overdose Treatment Portfolio with Exclusive KLOXXADO Rights - StockTitan
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - The Manila Times
Emergent BioSolutions Secures $16.7M BARDA Contract for Ebola Treatment Development - StockTitan
Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - MSN
HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS) - MarketBeat
Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365% - Yahoo Finance
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military - Marketscreener.com
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - The Manila Times
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Marketscreener.com
Emergent BioSolutions Secures $20M Defense Contract for Anthrax Vaccine BioThrax - StockTitan
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):